77 patents currently held
64 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Dec 2026. from the record
Of the 64 now held by other companies, 12 name Haleon US Holdings LLC as their current owner, and 52 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
45
Ending by 2030
Dec 2026
Next term end
47
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jan 2035 · High confidence
Also notable
Ends Dec 2026 · High confidence
Also notable
Ends Feb 2031 · High confidence
Phenyl Amino Pyrimidine Compounds and Uses Thereof
US 8,486,941
Cited by 83 later US patents, top 10% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2035.
Azaindole Inhibitors of Aurora Kinases
US 7,282,588
The most cited patent in this portfolio, cited by 112 later US patents, top 10% of utility patents granted in 2007 in our data. Protection runs to 2026.
(3S,11aR)-N-[2,4-Difluorophenyl)METHYL]-6-Hydroxy-3-Methyl-5,7-Dioxo-2,3,5,7,11,11a-HEXAHYDRO[1,3]OXAZOLO[3,2-a]PYRIDO[1,2-d]PYRAZINE-8-Carboxamide USEFUL AS ANTI-HIV AGENT
US 8,410,103
Cited by 36 later US patents, top 25% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
Formerly held, still cited
Notable
Ends Oct 2027 · High confidence
Cited by 77 later US patents, top 10% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
now held by Viiv Healthcare Company
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 14, 2026The maintenance fee for Methods of Producing Lyophilized Polypeptide Composition Formulations Comprising Volatile Additives (US 10,286,037) comes due Nov 14, 2026. Unpaid by May 14, 2027, it lapses early.
- 2 fees due Dec 11 to 23, 2026 · next Dec 11
- 1 fee due Jan 23, 2027The maintenance fee for Vapor Sheath for Liquid Dispensing Nozzle (US 10,357,798) comes due Jan 23, 2027. Unpaid by Jul 23, 2027, it lapses early.
- 2 fees due Feb 11, 2027
- 1 fee due Apr 13, 2027The maintenance fee for Benzimidazole Derivatives As PI3 Kinase Inhibitors (US 9,156,797) comes due Apr 13, 2027. Unpaid by Oct 13, 2027, it lapses early.
- 2 fees due May 3 to 19, 2027 · next May 3
- 2 fees due Jul 12 to 19, 2027 · next Jul 12
- 1 fee due Sep 17, 2027The maintenance fee for Substituted Bridged Urea Analogs as Sirtuin Modulators (US 10,590,135) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.
- 2 fees due Oct 19 to 23, 2027 · next Oct 19
Recent changes
- 4 terms have ended since Aug 16, 2026
What they patent
The 5 largest of its 47 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Prolyl Hydroxylase Inhibitors | 6 in force | to Dec 2028 |
| (N-(CYANOMETHYL)-4-(2-(4-Morpholinophenylamino)PYRIMIDIN-4-YL)BENZAMIDE | 4 in force | to Jun 2035 |
| Phenyl Amino Pyrimidine Compounds and Uses Thereof | 4 in force | to Jan 2035 |
| Benzimidazole Derivatives as PI3 Kinase Inhibitors | 4 in force | to Sep 2031 |
| Azaindole Inhibitors of Aurora Kinases | 4 in force | to Dec 2026 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,282,588 | Azaindole Inhibitors of Aurora Kinases In force · High confidence | In force | High confidence | |
| US 7,419,988 | Azaindole Inhibitors of Aurora Kinases In force · High confidence | In force | High confidence | |
| US 7,495,102 | Azaindole Inhibitors of Aurora Kinases In force · High confidence | In force | High confidence | |
| US 7,605,266 | Azaindole Inhibitors of Aurora Kinases In force · High confidence | In force | High confidence | |
| US 7,972,994 | Methods for Synthesis of Encoded Libraries In force · High confidence | In force | High confidence | |
| US 8,158,665 | Farnesoid X Receptor Agonists In force · High confidence | In force | High confidence | |
| US 7,838,540 | 3-Aminocarbonyl, 6-Phenyl Substituted PYRIDINE-1-Oxides as P38 Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 8,557,834 | Prolyl Hydroxylase Inhibitors In force · High confidence | In force | High confidence | |
| US 8,815,884 | Prolyl Hydroxylase Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 10,035,779 | Prolyl Hydroxylase Inhibitors In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 77: 64 patents in force now held by others · 420 patents ended · 21 applications pending · 211 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.